Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single-arm, Single-center Prospective Study of Anlotinib Hydrochloride and Toripalimab in Subjects With Unresectable or Metastatic Undifferentiated Pleomorphic Sarcoma Patients

NCT03946943 is registered in ClinicalTrials.gov with Di Wu as lead sponsor.

NCT NCT03946943
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03946943 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single-arm, Single-center Prospective Study of Anlotinib Hydrochloride and Toripalimab in Subjects With Unresectable or Metastatic Undifferentiated Pleomorphic Sarcoma Patients
Lead sponsor
Di Wu
Phase
Phase 2
Overall status
Unknown status
Start date
July 19, 2019
Completion date
July 19, 2023
Enrollment
25 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

soft tissue sarcomas, undifferentiated pleomorphic sarcoma